Novel Phenotyping for Acute Heart Failure—Unsupervised Machine Learning-Based Approach

• Main Authors: Berka, P. (Author), Biegus, J. (Author), Błaziak, M. (Author), Borkowski, A. (Author), Gajewski, P. (Author), Guzik, M. (Author), Iwanek, G. (Author), Jura, M. (Author), Pondel, M. (Author), Ponikowski, P. (Author), Siennicka, A. (Author), Urban, S. (Author), Zdanowicz, A. (Author), Zymliński, R. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: acute heart failure; clustering; machine learning
• Online Access: View Fulltext in Publisher

 Acute heart failure (AHF) is a life-threatening, heterogeneous disease requiring urgent diagnosis and treatment. The clinical severity and medical procedures differ according to a complex interplay between the deterioration cause, underlying cardiac substrate, and comorbidities. This study aimed to analyze the natural phenotypic heterogeneity of the AHF population and evaluate the possibilities offered by clustering (unsupervised machine-learning technique) in a medical data assessment. We evaluated data from 381 AHF patients. Sixty-three clinical and biochemical features were assessed at the admission of the patients and were included in the analysis after the preprocessing. The K-medoids algorithm was implemented to create the clusters, and optimization, based on the Davies-Bouldin index, was used. The clustering was performed while blinded to the outcome. The outcome associations were evaluated using the Kaplan-Meier curves and Cox proportional-hazards regressions. The algorithm distinguished six clusters that differed significantly in 58 variables concerning i.e., etiology, clinical status, comorbidities, laboratory parameters and lifestyle factors. The clusters differed in terms of the one-year mortality (p = 0.002) and two-year mortality (p = 0.002). Using the clustering techniques, we extracted six phenotypes from AHF patients with distinct clinical characteristics and outcomes. Our results can be valuable for future trial constructions and customized treatment. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.